Comparative Pharmacology
Head-to-head clinical analysis: EMRELIS versus PROCHLORPERAZINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMRELIS versus PROCHLORPERAZINE MALEATE.
EMRELIS vs PROCHLORPERAZINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
Prochlorperazine is a phenothiazine antipsychotic that primarily antagonizes dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and central nervous system. It also has anticholinergic and antiemetic effects through blockade of histamine H1 and muscarinic M1 receptors.
100 mg subcutaneously once weekly.
5-10 mg orally 3-4 times daily; or 25 mg rectally twice daily; or 5-10 mg intramuscularly every 3-4 hours up to 40 mg/day; or 2.5-10 mg intravenously slowly at 2.5 mg/min, maximum 20 mg/day.
None Documented
None Documented
12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 6-8 hours in adults, but may extend up to 12-15 hours after chronic dosing or in hepatic impairment.
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Primarily renal (70-80% as metabolites, <1% unchanged); fecal/biliary excretion accounts for 20-30% via enterohepatic circulation.
Category C
Category A/B
Antiemetic
Typical Antipsychotic / Antiemetic